Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon‐like peptide‐1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aim: To evaluate the safety and pharmacokinetics of cotadutide, a dual glucagon‐like peptide‐1 (GLP‐1) and glucagon receptor agonist, in overweight Asian participants with or without type 2 diabetes (T2D). Materials and Methods: In the phase 1, randomized, blinded, single‐ascending dose study, 24 Japanese and eight Chinese healthy adults (body mass index [BMI] 23‐40 kg/m 2 ) received one subcutaneous dose of cotadutide (50‐150 or 100 μg, respectively) or placebo. The primary endpoint was safety. In the phase 2a, randomized, double‐blinded, parallel dose‐ranging study with forced uptitration, 61 Japanese adults with T2D (BMI 24‐40 kg/m 2 ; HbA1c 7.0%‐10.5%) received cotadutide (100, 200, 300 μg) or placebo for 48 days. Co‐primary endpoints were safety/tolerability, change in glucose AUC 0‐4h and body weight. Results: Significant reductions from baseline to day 48 were observed with cotadutide for glucose AUC 0‐4h (33.6%‐42.1% reduction vs. +2.5% with placebo; 95% CIs: 100 μg −45.7%, −33.7%; 200 μg −35.6%, −23.7%; 300 μg −45.0%, −30.8%; placebo 3.4%, 8.3%) and body weight (1.3%‐2.5% decrease vs. +0.8% with placebo; 95% CIs: 100 μg −3.4%, −0.8%; 200 μg −4.7%, −2.0%; 300 μg −4.6%, −2.1%; placebo −2.1%, 0.4%). The most common adverse events with cotadutide were mild gastrointestinal symptoms with no serious adverse events. Increased pulse rate with cotadutide versus placebo is consistent with GLP‐1 monoagonists. Conclusions: Once‐daily cotadutide was effective and well tolerated up to 300 μg in overweight Japanese patients with T2D. Further evaluation in Asian populations is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 3×
“001).(15) Similar results were seen with semaglutide for death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke compared with placebo (hazard ratio 0.”
BackgroundResultSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
Zheng, Y., Ley, S. H., & Hu, F. B. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.151 · Cited by 5,697 · cited 1×
“increasing worldwide, suggesting that current treatment strategies do not adequately control disease burden.(1,2) The mean body mass index (BMI) of Japanese patients with T2D has gradually increased in recent years, and was 24.”
BackgroundHernandez, A. F., Green, J. B., Janmohamed, S., D'Agostino, R. B., Granger, C. B., Jones, N. P., Leiter, L. A., Rosenberg, A. E., Sigmon, K. N., Somerville, M. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32261-x · Cited by 1,829
Self-citationFrom NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Ambery, P., Parker, V. E., Stumvoll, M., Posch, M. G., Heise, T., Plum-Moerschel, L., Tsai, L.-F., Robertson, D., Jain, M., Petrone, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30726-8 · Cited by 298
Self-citationBoland, M. L., Laker, R. C., Mather, K., Nawrocki, A., Oldham, S., Boland, B. B., Lewis, H., Conway, J., Naylor, J., Guionaud, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0209-6 · Cited by 270 · cited 1×
“The potential therapeutic benefits of glucagon and GLP-1 dual agonism have been extensively described preclinically, where the glucagon activity of cotadutide resulted in significant reductions of steatosis, inflammation and fibrosis compared with a GLP-1 monoagonist.(10) In the first in-human phase 1 trial in healthy…”
BackgroundSelf-citationHenderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
Self-citationParker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123
Self-citationKumarathurai, P., Anholm, C., Larsen, B. S., Olsen, R. H., Madsbad, S., Kristiansen, O., Nielsen, O. W., Haugaard, S. B., & Sajadieh, A. (2017) · Diabetes Care · doi:10.2337/dc16-1580 · Cited by 96 · cited 1×
“2 kg.(16) Of note is that previous phase 3 trials showed a beneficial correlation between treatment with a GLP-1 receptor agonist (liraglutide, albiglutide or semaglutide) and cardiovascular outcomes in patients with T2D, with fewer deaths as a result of cardiovascular causes in the GLP-1 receptor agonist groups.”
BackgroundAmbery, P. D., Klammt, S., Posch, M. G., Petrone, M., Pu, W., Rondinone, C., Jermutus, L., & Hirshberg, B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13688 · Cited by 75 · cited 4×
“In the first in-human phase 1 trial in healthy volunteers, cotadutide (5-300 μg) dose-dependently reduced glucose within the normal range with no rise in blood glucose, with a pharmacokinetic profile that supported once-daily dosing.(11) Dose escalations were necessary to minimize the incidence of gastrointestinal adv…”
BackgroundResultSelf-citation
Cited by
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211
Self-citationGut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Zhang, B., Cheng, Z., Chen, J., Zhang, X., Liu, D., Jiang, H., Ma, G., Wang, X., Gan, S., Sun, J., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1287 · Cited by 91
Ji, L., Jiang, H., An, P., Deng, H., Liu, M., Li, L., Feng, L., Song, B., Han-Zhang, H., Ma, Q., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101088 · Cited by 63
Metadata
- Authors
- Asano, M., Sekikawa, A., Kim, H., Gasser, R. A., Robertson, D., Petrone, M., Jermutus, L., & Ambery, P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2021-05-19
- Volume
- 23
- Issue
- 8
- Pages
- 1859-1867
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3159068931
- Cited by
- 38
- References
- 11
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.